CONTACT US: Contact info
|
Citation |
Parker C. Medicine (Abingdon) 2012; 40(12): 691-695. |
|
Copyright |
(Copyright © 2012, Medicine Publishing) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
Psychiatric adverse drug reactions (ADRs) have been reported with a diverse range of medicines used in the treatment of physical illness. Whereas some are mild (such as transient sleep disturbances), others are severe (such as psychosis) and warrant discontinuation of the suspected causal agents. Some reactions are predictable, while others are unpredictable. The mechanism by which they are mediated is often unclear. It is essential that serious psychiatric ADRs observed during routine clinical practice be reported via the UK's Yellow Card reporting scheme as many are relatively uncommon and may only be detected through postmarketing surveillance in the wider population. Patients have reported finding symptoms of psychiatric ADRs extremely distressing and sometimes frightening, and may be hesitant to mention these to prescribers. © 2012 Elsevier Ltd. All rights reserved. Language: en |
|
Keywords |
human; suicide; insomnia; depression; aggression; anxiety; psychosis; behavior change; risk assessment; mood disorder; lamivudine; emotional disorder; review; fatigue; mental disease; antisocial behavior; cognitive defect; sedation; selegiline; priority journal; hallucination; somnolence; paranoia; anxiety disorder; sleep disorder; panic; hydroxymethylglutaryl coenzyme A reductase inhibitor; hostility; confusion; efavirenz; opiate derivative; carbamazepine; beta adrenergic receptor blocking agent; akathisia; dysphoria; restlessness; irritability; delirium; nightmare; unindexed drug; valproic acid; catatonia; mania; side effect; symptom; topiramate; vigabatrin; hypomania; agitation; phenytoin; levodopa; postmarketing surveillance; calcium channel blocking agent; mental instability; etiracetam; paresthesia; dipeptidyl carboxypeptidase inhibitor; amantadine; depersonalization; didanosine; zidovudine; penicillin G; tetracycline; lethargy; sumatriptan; euphoria; muscarinic receptor blocking agent; mood change; chloroquine; mefloquine; visual hallucination; dopamine receptor stimulating agent; dysphonia; vivid dream; abnormal dreaming; entacapone; ethosuximide; adverse drug reaction; cephalosporin derivative; psychiatric adverse effect; quinolone |